{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:27:01Z","timestamp":1791584821540,"version":"4.3.4"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2024-MS-024"],"award-info":[{"award-number":["2024-MS-024"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neuroscience.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:31:22Z","timestamp":1773073882000},"page":"155-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Harmine and its derivatives: A promising multi-target therapeutic avenue for Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"601","author":[{"given":"Xue","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Nao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2026.03.006_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.178288","article-title":"Active immunization: a novel therapeutic strategy for treating Alzheimer\u2019s disease","volume":"1007","author":"Mazahir","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2215-0366(15)00454-X","article-title":"Development of interventions for the secondary prevention of Alzheimer\u2019s dementia: the European Prevention of Alzheimer\u2019s Dementia (EPAD) project","volume":"3","author":"Ritchie","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0015","doi-asserted-by":"crossref","unstructured":"GBD 2019 Dementia Forecasting Collaborators, 2022. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7:e105\u2013e125. Doi: 10.1016\/S2468-2667(21)00249-8.","DOI":"10.1016\/S2468-2667(21)00249-8"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0020","article-title":"Review of anti-amyloid-beta (A\u03b2) monoclonal antibodies for the treatment of Alzheimer\u2019s disease","volume":"1\u201316","author":"Francis","year":"2025","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0025","doi-asserted-by":"crossref","first-page":"9240","DOI":"10.7150\/thno.118409","article-title":"Targeted autophagic clearance of Tau protects against Alzheimer\u2019s disease through amelioration of Tau-mediated lysosomal stress","volume":"15","author":"Yoon","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0030","doi-asserted-by":"crossref","first-page":"25551","DOI":"10.31083\/FBL25551","article-title":"The potential mechanism and the role of antioxidants in mitigating oxidative stress in Alzheimer\u2019s disease","volume":"30","author":"Naik","year":"2025","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0035","article-title":"The effects of microglia-associated neuroinflammation on Alzheimer\u2019s disease","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0040","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0045","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.biopsych.2024.12.009","article-title":"A multiform heterogeneity framework for Alzheimer\u2019s disease based on multimodal neuroimaging","volume":"97","author":"Zhao","year":"2025","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0050","doi-asserted-by":"crossref","DOI":"10.1007\/s11030-025-11170-1","article-title":"Innovative approaches in acetylcholinesterase inhibition: a pathway to effective Alzheimer\u2019s disease treatment","author":"Arora","year":"2025","journal-title":"Mol. Divers."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0055","article-title":"Memantine: updates from the past decade and implications for future novel therapeutic applications","volume":"1996","author":"Danysz","year":"2025","journal-title":"J. Neural Transm. (Vienna Austria)"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/pmic.70006","article-title":"Memantine administration enhances glutamatergic and GABAergic pathways in the human hippocampus of Alzheimer\u2019s disease patients","volume":"25","author":"Fabrik","year":"2025","journal-title":"Proteomics"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0070","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1474-4422(25)00313-8","article-title":"Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer\u2019s disease treated with aducanumab versus untreated: a retrospective case-control study","volume":"24","author":"Boon","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1326784","article-title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","volume":"18","author":"Doran","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117277","article-title":"Analysis of skeletal diversity of multi-target directed ligands (MTDLs) targeting Alzheimer\u2019s disease","volume":"286","author":"Azam","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108666","article-title":"Unveiling the potential of novel natural product-based MTDLs that integrate cinnamamide scaffold as multifunctional agents for the treatment of Alzheimer\u2019s disease","volume":"163","author":"Shaaban","year":"2025","journal-title":"Bioorganic Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0090","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1007\/s12035-022-02859-7","article-title":"Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer\u2019s disease from bench to bedside","volume":"59","author":"Islam","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0095","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11033-025-10543-x","article-title":"MicroRNAs modulation by curcumin, catalpol, and other natural products in Alzheimer\u2019s disease: a review","volume":"52","author":"Chahardehi","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.neulet.2014.09.023","article-title":"Harmine mediated neuroprotection via evaluation of glutamate transporter 1 in a rat model of global cerebral ischemia","volume":"583","author":"Sun","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/1568007043482499","article-title":"Cholinergic activity and amyloid precursor protein processing in aging and Alzheimer\u2019s disease","volume":"3","author":"Zhang","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0110","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/molecules27061816","article-title":"Role of cholinergic signaling in Alzheimer\u2019s disease","volume":"27","author":"Chen","year":"2022","journal-title":"Molecules (Basel Switz.)"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2025.149600","article-title":"Reduction in [18F]Nifene binding, a PET imaging probe for \u03b14\u03b22* nicotinic acetylcholinergic receptors in hippocampus-subiculum of postmortem human Alzheimer\u2019s disease brain","volume":"1857","author":"Karim","year":"2025","journal-title":"Brain Res."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0120","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0125","doi-asserted-by":"crossref","first-page":"8726","DOI":"10.3390\/ijms26178726","article-title":"Acetylcholinesterase as a multifunctional target in amyloid-driven neurodegeneration: from dual-site inhibitors to anti-agregation strategies","volume":"26","author":"Grabowska","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnins.2019.00038","article-title":"Innovative therapy for Alzheimer\u2019s disease-with focus on biodelivery of NGF","volume":"13","author":"Mitra","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0135","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3390\/ijms18061319","article-title":"The intersection of NGF\/TrkA signaling and amyloid precursor protein processing in Alzheimer\u2019s disease neuropathology","volume":"18","author":"Canu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fnins.2019.00062","article-title":"The brain NGF metabolic pathway in health and in Alzheimer\u2019s pathology","volume":"13","author":"Cuello","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-030-74046-7_4","article-title":"The NGF metabolic pathway: new opportunities for biomarker research and drug target discovery: NGF pathway biomarkers and drug targets","volume":"1331","author":"Pentz","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0150","article-title":"Electroacupuncture regulates Rab5a-mediating NGF transduction to improve learning and memory ability in the early stage of AD mice","volume":"30","author":"Li","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3233\/JHD-120026","article-title":"NGF rescues hippocampal cholinergic neuronal markers, restores neurogenesis, and improves the spatial working memory in a mouse model of Huntington\u2019s Disease","volume":"2","author":"Zhang","year":"2013","journal-title":"J. Huntingt. Dis."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fncel.2017.00068","article-title":"Impaired NGF\/TrkA signaling causes early AD-linked presynaptic dysfunction in cholinergic primary neurons","volume":"11","author":"Latina","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0165","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1007\/s12035-024-04543-4","article-title":"Morphological and molecular profiling of amyloid-\u03b2 species in Alzheimer\u2019s pathogenesis","volume":"62","author":"Almeida","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0170","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00401-010-0719-5","article-title":"Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer\u2019s disease pathogenesis","volume":"120","author":"Boche","year":"2010","journal-title":"Acta Neuropathol. (Berl)"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer\u2019s disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0180","doi-asserted-by":"crossref","first-page":"440","DOI":"10.5582\/ddt.2023.01215","article-title":"Development of amyloid beta-directed antibodies against Alzheimer\u2019s disease: twists and turns","volume":"17","author":"Lu","year":"2023","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0185","doi-asserted-by":"crossref","DOI":"10.1002\/syn.70024","article-title":"[125I]IPPI for tau imaging: binding studies in postmortem human Alzheimer\u2019s disease hippocampus-subiculum and evaluation of drug effects","volume":"79","author":"Karim","year":"2025","journal-title":"Synapse"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0190","article-title":"Biomolecular phase separation of microtubule-associated protein tau and its role in the genesis of brain disorders","volume":"113","author":"Bhandari","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0195","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1021\/acschemneuro.8b00457","article-title":"Pathological changes of Tau related to Alzheimer\u2019s disease","volume":"10","author":"Chu","year":"2019","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0200","doi-asserted-by":"crossref","first-page":"24374","DOI":"10.1016\/S0021-9258(20)80536-5","article-title":"Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease","volume":"268","author":"K\u00f6pke","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0205","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.neuron.2011.04.009","article-title":"The many faces of tau","volume":"70","author":"Morris","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0210","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00401-024-02839-2","article-title":"Amyloid-\u03b2 oligomers increase the binding and internalization of tau oligomers in human synapses","volume":"149","author":"Kadamangudi","year":"2024","journal-title":"Acta Neuropathol. (Berl)"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0215","article-title":"Protein kinases in Alzheimer\u2019s disease: pioneering insights into pathogenesis and therapeutic breakthroughs","author":"Lari","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0220","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.3233\/JAD-231238","article-title":"Tau immunotherapies for Alzheimer\u2019s disease and related tauopathies: status of trials and insights from preclinical studies","volume":"101","author":"Sigurdsson","year":"2024","journal-title":"J. Alzheimers Dis. JAD"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?","volume":"17","author":"Leng","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/13872877241313223","article-title":"Microglial polarization in Alzheimer\u2019s disease: mechanisms, implications, and therapeutic opportunities","volume":"104","author":"Yang","year":"2025","journal-title":"J. Alzheimers Dis. JAD"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0235","doi-asserted-by":"crossref","first-page":"10808","DOI":"10.3390\/ijms241310808","article-title":"Comparison of monoamine oxidase-a, A\u03b2 plaques, tau, and translocator protein levels in postmortem human Alzheimer\u2019s disease brain","volume":"24","author":"Syed","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0240","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2174\/156802612805219950","article-title":"Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival","volume":"12","author":"Naoi","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0245","doi-asserted-by":"crossref","first-page":"44212","DOI":"10.1038\/s41598-025-32012-y","article-title":"Design, synthesis, and multi-target evaluation of 4-phenyl quinoline-8-sulfonate thiosemicarbazones as potential anti-Alzheimer agents","volume":"15","author":"Saeed","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101622","article-title":"Glial cells in Alzheimer\u2019s disease: from neuropathological changes to therapeutic implications","volume":"78","author":"Uddin","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0255","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.4103\/1673-5374.306064","article-title":"Astrocytes: a double-edged sword in neurodegenerative diseases","volume":"16","author":"Ding","year":"2021","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0260","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","article-title":"Neuroinflammation in Alzheimer\u2019s disease: current evidence and futuredirections","volume":"12","author":"Calsolaro","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0265","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/42257","article-title":"Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E","volume":"388","author":"Barger","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0270","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70746","article-title":"Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegeneration","volume":"21","author":"Povala","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0275","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3389\/fimmu.2020.00724","article-title":"TLR4 cross-talk with NLRP3 inflammasome and complement signaling pathways in Alzheimer\u2019s disease","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.772717","article-title":"Microglia polarization in Alzheimer\u2019s disease: mechanisms and a potential therapeutic target","volume":"13","author":"Wang","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0285","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","article-title":"Tau and neuroinflammation in Alzheimer\u2019s disease: interplay mechanisms and clinical translation","volume":"20","author":"Chen","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0290","article-title":"Glutamatergic receptor expression changes in the Alzheimer\u2019s disease hippocampus and entorhinal cortex","volume":"31","author":"Yeung","year":"2021","journal-title":"Brain Pathol. (Zurich Switz.)"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.03.002","article-title":"The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: potential targets for neurotherapeutics","volume":"161","author":"Pajarillo","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2025.115804","article-title":"Neuroprotective role of GLT-1\/EAAT2 in glutamate-induced excitotoxicity","volume":"495","author":"Zhang","year":"2025","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2024.114967","article-title":"Common and divergent pathways in early stages of glutamate and tau-mediated toxicities in neurodegeneration","volume":"382","author":"Chongtham","year":"2024","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2025.1617006","article-title":"Reduction of the Ca2+ permeability of ligand-gated ion channels as a strategy against excitotoxicity","volume":"19","author":"D\u2019Andrea","year":"2025","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0315","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1007\/s11571-024-10064-6","article-title":"A\u03b2-mediated synaptic glutamate dynamics and calcium dynamics in astrocytes associated with Alzheimer\u2019s disease","volume":"18","author":"Li","year":"2024","journal-title":"Cogn. Neurodyn."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2023.102534","article-title":"The role of N-methyl-D-aspartate glutamate receptors in Alzheimer\u2019s disease: from pathophysiology to therapeutic approaches","volume":"231","author":"Liu","year":"2023","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0325","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/jnc.15099","article-title":"Amyloid-beta1-42 induced glutamatergic receptor and transporter expression changes in the mouse hippocampus","volume":"155","author":"Yeung","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0330","article-title":"Tau pathology is associated with postsynaptic metabotropic glutamate receptor 5 (mGluR5) in early Alzheimer\u2019s disease in a sex-specific manner","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0335","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.3390\/ijms251810220","article-title":"NMDARs in Alzheimer\u2019s disease: between synaptic and extrasynaptic membranes","volume":"25","author":"Escamilla","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0340","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/molecules29010020","article-title":"Glutamate\u2019s effects on the N-methyl-D-aspartate (NMDA) receptor ion channel in Alzheimer\u2019s disease brain: challenges for PET radiotracer development for imaging the NMDA ion channel","volume":"29","author":"Shah","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0345","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S2221-1691(12)60116-6","article-title":"A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid \u201c\u2018Harmine.\u2019","volume":"2","author":"Patel","year":"2012","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0350","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12931-025-03196-8","article-title":"Harmine alleviates LPS-induced acute lung injury by inhibiting CSF3-mediated MAPK\/NF-\u03baB signaling pathway","volume":"26","author":"Zhai","year":"2025","journal-title":"Respir. Res."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107676","article-title":"Design, synthesis, and biological evaluation of \u03b2-carboline-cinnamic acid derivatives as DYRK1A inhibitors in the treatment of diabetes","volume":"151","author":"Guan","year":"2024","journal-title":"Bioorganic Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0360","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.3390\/molecules26196084","article-title":"Antioxidant and anti-inflammatory effects of peganum harmala extracts: an in vitro and in vivo study","volume":"26","author":"Abbas","year":"2021","journal-title":"Molecules (Basel Switz.)"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0365","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s43440-024-00602-8","article-title":"Unraveling the mechanistic interplay of mediators orchestrating the neuroprotective potential of harmine","volume":"76","author":"Kadyan","year":"2024","journal-title":"Pharmacol. Rep. PR"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0370","article-title":"Research progress on the antitumor effects of harmine","volume":"14","author":"Hu","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0375","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41401-021-00639-y","article-title":"Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy","volume":"43","author":"Huang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0380","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s11011-024-01416-6","article-title":"Peganum harmala L. seed extract attenuates anxiety and depression in rats by reducing neuroinflammation and restoring the BDNF\/TrkB signaling pathway and monoamines after exposure to chronic unpredictable mild stress","volume":"39","author":"Tek\u015fen","year":"2024","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0385","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2015.10.037","article-title":"Effects of harmine, an acetylcholinesterase inhibitor, on spatial learning and memory of APP\/PS1 transgenic mice and scopolamine-induced memory impairment mice","volume":"768","author":"He","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0390","article-title":"Mechanism-based pharmacokinetics-pharmacodynamics studies of harmine and harmaline on neurotransmitters regulatory effects in healthy rats: challenge on monoamine oxidase and acetylcholinesterase inhibition","volume":"62","author":"Jiang","year":"2019","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019264","article-title":"\u03b2-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer\u2019s disease-related sites","volume":"6","author":"Frost","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113554","article-title":"Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3\u03b2\/DYRK1A dual inhibitors for the treatment of Alzheimer\u2019s disease","volume":"222","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0405","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.neuropharm.2010.10.016","article-title":"Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression","volume":"60","author":"Li","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0410","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/14756366.2014.940932","article-title":"Synthesis of new isoxazoline derivatives from harmine and evaluation of their anti-Alzheimer, anti-cancer and anti-inflammatory activities","volume":"30","author":"Filali","year":"2015","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0415","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.physbeh.2014.09.001","article-title":"Harmine treatment enhances short-term memory in old rats: dissociation of cognition and the ability to perform the procedural requirements of maze testing","volume":"138","author":"Mennenga","year":"2015","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0420","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3389\/fphar.2018.00346","article-title":"Analogous \u03b2-carboline alkaloids harmaline and harmine ameliorate scopolamine-induced cognition dysfunction by attenuating acetylcholinesterase activity, oxidative stress, and inflammation in mice","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115521","article-title":"Function and inhibition of DYRK1A: emerging roles of treating multiple human diseases","volume":"212","author":"Yang","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0430","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2024.2418470","article-title":"Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-\u03b2 formation","volume":"39","author":"Tu","year":"2024","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0435","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1587089","article-title":"DYRK1A in blood and immune function: implications in leukemia, inflammatory disorders, infection and down syndrome","volume":"13","author":"Rozen","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0440","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/s41380-024-02865-2","article-title":"Lithium normalizes ASD-related neuronal, synaptic, and behavioral phenotypes in DYRK1A-knockin mice","volume":"30","author":"Roh","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0445","doi-asserted-by":"crossref","first-page":"8809","DOI":"10.1007\/s12035-025-04806-8","article-title":"Unlocking the therapeutic potential of the dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitors in Alzheimer\u2019s diseases","volume":"62","author":"Karati","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0450","doi-asserted-by":"crossref","first-page":"30851","DOI":"10.1074\/jbc.M110.110957","article-title":"Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration","volume":"285","author":"Alonso","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0455","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00401-020-02251-6","article-title":"Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation","volume":"141","author":"Arag\u00e3o Gomes","year":"2021","journal-title":"Acta Neuropathol. (Berl)"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0460","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fnagi.2013.00098","article-title":"Neprilysin and A\u03b2 clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer\u2019s disease","volume":"5","author":"Grimm","year":"2013","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0465","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3390\/brainsci15101101","article-title":"Therapeutic advances in targeting the amyloid-\u03b2 pathway for Alzheimer\u2019s disease","volume":"15","author":"Zhang","year":"2025","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0470","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1471-4159.2007.05075.x","article-title":"Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between down syndrome and Alzheimer\u2019s disease","volume":"104","author":"Ryoo","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0475","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1471-4159.2010.06769.x","article-title":"Dyrk1A-mediated phosphorylation of presenilin 1: a functional link between down syndrome and Alzheimer\u2019s disease","volume":"115","author":"Ryu","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0480","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1248\/bpb.b16-00825","article-title":"Neprilysin is suppressed by dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) in down-syndrome-derived fibroblasts","volume":"40","author":"Kawakubo","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0485","doi-asserted-by":"crossref","first-page":"9670","DOI":"10.3390\/ijms26199670","article-title":"The central cholinergic synapse: a primer","volume":"26","author":"Klein","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0490","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500053","article-title":"The evolution of AChE inhibitors in Alzheimer\u2019s disease: from single-target to multi-target ligands","volume":"26","author":"Mehta","year":"2025","journal-title":"Chembiochem. Eur. J. Chem. Biol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0495","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.3390\/ijms24054399","article-title":"Natural alkaloids as multi-target compounds towards factors implicated in Alzheimer\u2019s disease","volume":"24","author":"Vrabec","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0500","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbr.2015.11.023","article-title":"Fractal dimensions: a new paradigm to assess spatial memory and learning using Morris water maze","volume":"299","author":"Singh","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0505","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature04631","article-title":"A genome-wide drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT","volume":"441","author":"Gwack","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0510","doi-asserted-by":"crossref","first-page":"39819","DOI":"10.1074\/jbc.M104091200","article-title":"Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells","volume":"276","author":"Yang","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0515","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.15252\/embr.201540374","article-title":"DYRK1A overexpression enhances STAT activity and astrogliogenesis in a down syndrome mouse model","volume":"16","author":"Kurabayashi","year":"2015","journal-title":"EMBO Rep."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0520","doi-asserted-by":"crossref","first-page":"31895","DOI":"10.1074\/jbc.M110.147520","article-title":"Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells","volume":"285","author":"Park","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0525","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1242\/jcs.044354","article-title":"Attenuation of Notch signalling by the down-syndrome-associated kinase DYRK1A","volume":"122","author":"Fernandez-Martinez","year":"2009","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0530","first-page":"1117","article-title":"Novel hybrid peptide DEFB126 (1-39)-TP5 inhibits LPS-induced inflammatory responses and oxidative stress by neutralizing LPS and blocking the TLR4\/MD2-NF\u03baB signaling axis","volume":"14","author":"Tang","year":"2025","journal-title":"Antioxidants (Basel Switz.)"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0535","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s10753-022-01699-w","article-title":"Inhibition of Dyrk1A attenuates LPS-induced neuroinflammation via the TLR4\/NF-\u03baB P65 signaling pathway","volume":"45","author":"Ju","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0540","doi-asserted-by":"crossref","first-page":"F1034","DOI":"10.1152\/ajprenal.00414.2005","article-title":"Sepsis induces changes in the expression and distribution of Toll-like receptor 4 in the rat kidney","volume":"290","author":"El-Achkar","year":"2006","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0545","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00018-020-03656-y","article-title":"TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling","volume":"78","author":"Ciesielska","year":"2021","journal-title":"Cell Mol. Life Sci. CMLS"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115196","article-title":"Huang-Lian-Jie-Du decoction attenuates cognitive dysfunction of rats with type 2 diabetes by regulating autophagy and NLRP3 inflammasome activation","volume":"292","author":"Tian","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0555","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/molecules23030522","article-title":"Inhibiting the NLRP3 inflammasome activation with MCC950 ameliorates diabetic encephalopathy in db\/db mice","volume":"23","author":"Zhai","year":"2018","journal-title":"Molecules (Basel Switz.)"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0560","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fphar.2020.00535","article-title":"Harmine ameliorates cognitive impairment by inhibiting NLRP3 inflammasome activation and enhancing the BDNF\/TrkB signaling pathway in STZ-induced diabetic rats","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0565","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/glia.10310","article-title":"Glutamate transporter expression and function in human glial progenitors","volume":"45","author":"Maragakis","year":"2004","journal-title":"Glia"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0570","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3389\/fneur.2019.01041","article-title":"Upregulation of GLT-1 via PI3K\/Akt pathway contributes to neuroprotection induced by dexmedetomidine","volume":"10","author":"Peng","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0575","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejphar.2010.04.021","article-title":"Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia\/reperfusion injury","volume":"638","author":"Verma","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0580","doi-asserted-by":"crossref","unstructured":"Shi, J.-H., Tang, Q.-L., Wang, J.-H., et al., 2025 Pigment epithelium-derived factor deficiency impairs hippocampal glutamate homeostasis and cognitive function by downregulating astrocytic GLT-1. Adv. Sci. Weinh. Baden-Wurtt Ger., e00402. Doi: 10.1002\/advs.202500402.","DOI":"10.1002\/advs.202500402"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0585","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1084\/jem.20140413","article-title":"Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer\u2019s disease","volume":"212","author":"Takahashi","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115169","article-title":"Thioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer\u2019s disease","volume":"250","author":"Tonelli","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114305","article-title":"Novel inhibitors of AChE and A\u03b2 aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer\u2019s disease","volume":"235","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0600","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2281893","article-title":"Novel harmine derivatives as potent acetylcholinesterase and amyloid beta aggregation dual inhibitors for management of Alzheimer\u2019s disease","volume":"38","author":"Du","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0605","article-title":"Zileuton protects against arachidonic acid\/5-lipoxygenase\/leukotriene axis-mediated neuroinflammation in experimental traumatic brain injury","volume":"16","author":"Xu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0610","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1007\/s10787-024-01557-1","article-title":"Leukotriene signaling in neurodegeneration: implications for treatment strategies","volume":"32","author":"Sharma","year":"2024","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0615","doi-asserted-by":"crossref","first-page":"18286","DOI":"10.1038\/srep18286","article-title":"Inflammatory eicosanoids increase amyloid precursor protein expression via activation of multiple neuronal receptors","volume":"5","author":"Herbst-Robinson","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0620","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.neurobiolaging.2013.09.036","article-title":"Involvement of cysteinyl leukotriene receptor 1 in A\u03b21-42-induced neurotoxicity in vitro and in vivo","volume":"35","author":"Tang","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0625","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbi.2016.10.021","article-title":"Preventive effect of genetic knockdown and pharmacological blockade of CysLT1R on lipopolysaccharide (LPS)-induced memory deficit and neurotoxicity in vivo","volume":"60","author":"Chen","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0630","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pnpbp.2016.10.001","article-title":"CysLT1R downregulation reverses intracerebroventricular streptozotocin-induced memory impairment via modulation of neuroinflammation in mice","volume":"73","author":"Ghosh","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0635","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1742-2094-9-127","article-title":"Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer\u2019s disease mouse model","volume":"9","author":"Chu","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0640","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.3233\/JAD-179931","article-title":"Novel key players in the development of tau neuropathology: focus on the 5-lipoxygenase","volume":"64","author":"Lauretti","year":"2018","journal-title":"J. Alzheimers Dis. JAD"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0645","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.neurobiolaging.2012.12.009","article-title":"5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5","volume":"34","author":"Chu","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0650","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12759","article-title":"Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice","volume":"17","author":"Giannopoulos","year":"2018","journal-title":"Aging Cell"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0655","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10571-020-01020-z","article-title":"GSK-3\u03b2 disrupts neuronal oscillatory function to inhibit learning and memory in male rats","volume":"42","author":"Albeely","year":"2022","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116065","article-title":"Targeting glycogen synthase kinase-3\u03b2 for Alzheimer\u2019s disease: recent advances and future prospects","volume":"265","author":"Cheng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0665","article-title":"Glycogen synthase kinase-3 signaling in Alzheimer\u2019s disease","volume":"1867","author":"Lauretti","year":"2020","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0670","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1007\/s12035-023-03839-1","article-title":"Understanding glycogen synthase kinase-3: a novel avenue for Alzheimer\u2019s disease","volume":"61","author":"Sequeira","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0675","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1042\/bj3550609","article-title":"The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase","volume":"355","author":"Woods","year":"2001","journal-title":"Biochem. J"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0680","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3390\/molecules30050990","article-title":"Towards imaging tau hyperphosphorylation: is DYRK1A a potential target for imaging hyperphosphorylation of tau? Molecular modeling assessment and synthesis of [125I]radioiodinated DYRK1A inhibitor","volume":"30","author":"Paclibar","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109525","article-title":"An inhibitor with GSK3\u03b2 and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer\u2019s disease","volume":"232","author":"Liu","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0690","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","article-title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","volume":"13","author":"Bayoumy","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0695","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300404","article-title":"Discovery of novel harmine derivatives as GSK-3\u03b2\/DYRK1A dual inhibitors for Alzheimer\u2019s disease treatment","volume":"357","author":"Qiu","year":"2024","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114095","article-title":"Discovery of novel \u03b2-carboline derivatives as selective AChE inhibitors with GSK-3\u03b2 inhibitory property for the treatment of Alzheimer\u2019s disease","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0705","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2025.1545908","article-title":"Bis(7)-harmine derivatives as potential multi-target anti-Alzheimer agents","volume":"13","author":"Du","year":"2025","journal-title":"Front. Chem."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0710","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2131\/jts.46.289","article-title":"Central inhibition prevents the in vivo acute toxicity of harmine in mice","volume":"46","author":"Lv","year":"2021","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0715","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.neuro.2023.10.005","article-title":"Harmaline toxicity on dorsal striatal neurons and its role in tremor","volume":"99","author":"Zhan","year":"2023","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuroscience.2026.03.006_b0720","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/jps.2600660910","article-title":"Cardiovascular actions of three harmala alkaloids: harmine, harmaline, and harmalol","volume":"66","author":"Aarons","year":"1977","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.neuroscience.2026.03.006_b0725","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70124","article-title":"The enhancing effects of selenomethionine on harmine in attenuating pathological cardiac hypertrophy via glycolysis metabolism","volume":"28","author":"Chen","year":"2024","journal-title":"J. Cell Mol. Med."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226001697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226001697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:19:24Z","timestamp":1779337164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226001697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":145,"alternative-id":["S0306452226001697"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.03.006","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harmine and its derivatives: A promising multi-target therapeutic avenue for Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}